Need of booster vaccine doses to counteract the emergence of SARS-CoV-2 variants in the context of the Omicron variant and increasing COVID-19 cases: An update

The emergence of different variants of SARS-CoV-2, including the Omicron (B.1.1.529) variant in November 2021, has resulted in a continuous major health concern at a global scale. Presently, the Omicron variant has spread very rapidly worldwide within a short time period. As the most mutated variant...

Full description

Saved in:
Bibliographic Details
Published in:Human vaccines & immunotherapeutics 2022-11, Vol.18 (5), p.2065824-2065824
Main Authors: Mohapatra, Ranjan K., El-Shall, Nahed A., Tiwari, Ruchi, Nainu, Firzan, Kandi, Venkataramana, Sarangi, Ashish K., Mohammed, Teroj Abdulrahman, Desingu, Perumal Arumugam, Chakraborty, Chiranjib, Dhama, Kuldeep
Format: Article
Language:English
Subjects:
B.1.1.529
booster doses
Coronavirus
COVID-19 - prevention & control
COVID-19 Vaccines
enhancing immunity
Humans
Omicron variant
protection
SARS-CoV-2
SARS-CoV-2 - genetics
vaccines
Viral Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The emergence of different variants of SARS-CoV-2, including the Omicron (B.1.1.529) variant in November 2021, has resulted in a continuous major health concern at a global scale. Presently, the Omicron variant has spread very rapidly worldwide within a short time period. As the most mutated variant of SARS-CoV-2, Omicron has instilled serious uncertainties on the effectiveness of humoral adaptive immunity generated by COVID-19 vaccination or an active viral infection as well as the protection provided by antibody-based immunotherapies. Amidst such high public health concerns, the need to carry out booster vaccination has been emphasized. Current evidence reveals the importance of incorporating booster vaccination using several vaccine platforms, such as viral vector- and mRNA-based vaccines, as well as other platforms that are under explorative investigations. Further research is being conducted to assess the effectiveness and durability of protection provided by booster COVID-19 vaccination against Omicron and other SARS-CoV-2 variants.
ISSN:2164-5515
2164-554X
DOI:10.1080/21645515.2022.2065824